Pilot RCT of Angiotensin II vs. Vasopressin in Septic Shock
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This will be a randomized controlled unblinded pragmatic single-center pilot trial of the use
of vasopressin vs. angiotensin II as a second-line vasopressor in patients with septic shock
and persistent hypotension despite moderate-to-high doses of norepinephrine.
Phase:
Phase 4
Details
Lead Sponsor:
University of New Mexico
Collaborators:
La Jolla Pharmaceutical Company National Center for Advancing Translational Science (NCATS)
Treatments:
Angiotensin II Angiotensinogen Arginine Vasopressin Giapreza Vasopressins